The Economic Costs for the Control of Cardiovascular Risk: An Overview

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|13|2447-2453

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.13, 2013-04, pp. : 2447-2453

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular drugs and the risk of suicide: a nested case-control study

By Callréus Torbjörn   Agerskov Andersen Ulla   Hallas Jesper   Andersen Morten  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 6, 2007-06 ,pp. : 591-596

Springer Publishing Company

Access to resources Recommend Favorite

A New Approach to Risk Assessment Integrating Scientific Evaluation and Economic Assessment of Costs and Benefits

By Barnard R.C.  

Regulatory Toxicology and Pharmacology, Vol. 24, Iss. 2, 1996-10 ,pp. : 121-125

Academic Press

Access to resources Recommend Favorite

Depression increases cardiovascular healthcare costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 571, 2009-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Inpatient Costs of Major Cardiovascular Events

By Radensky P.W.  

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 3, 2001-03 ,pp. : 205-217

Adis International

Access to resources Recommend Favorite

Soaring costs of cardiovascular disease in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 621, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite